Optimization of prescription of potassium chloride cyclopentazide sustained-release tablets by the Box-Behnken central composite design
WANG Mengnan;LI Yan;LI Yan;WU Jingjing;SHI Kai;School of Pharmacy, Shenyang Pharmaceutical University;
Objective To control the release behavior of potassium chloride cyclopentazide sustained-release tablets by skeleton materials and coating membrane, and to screen the optimizing prescription by using the Box-Benhnken central composite design principle. Methods Eudragit RS PO was used as the skeleton material to prepare the core, and Eudragit RS100 and Eudragit RL100 were mixed by a certain proportion to prepare the coating material. The optimal prescription is determined by using the design expert software to process data. Results The dosage of Eudragit RS PO was 6.78%, and the proportion of Eudragit RS100 and Eudragit RL100 was 52:48, and the coating weight was increased by 3%. Conclusion The combination of skeleton material and coating membrane can effectively control release rate of the potassium chloride cyclopentazide sustained-release tablets, and the optimal prescription screened by the Box-Behnken central composite design principle can achieve the expected effect.
【CateGory Index】： R91